
TY  - JOUR
TI  - Oral Presentations
JO  - Neurogastroenterology & Motility
JA  - Neurogastroenterol. Motil.
VL  - 28
IS  - S1
SN  - 1350-1925
UR  - https://doi.org/10.1111/nmo.12881
DO  - doi:10.1111/nmo.12881
SP  - 5
EP  - 108
PY  - 2016
ER  - 

TY  - JOUR
TI  - Abstracts TPS
JO  - Allergy
JA  - Allergy
VL  - 73
IS  - S105
SN  - 0105-4538
UR  - https://doi.org/10.1111/all.13539
DO  - doi:10.1111/all.13539
SP  - 370
EP  - 702
PY  - 2018
ER  - 

TY  - JOUR
TI  - Posters
JO  - Clinical Microbiology and Infection
VL  - 16
IS  - s2
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1469-0691.2010.03239.x
DO  - doi:10.1111/j.1469-0691.2010.03239.x
SP  - S133
EP  - S634
PY  - 2010
ER  - 

TY  - JOUR
TI  - Keyword index
JO  - Journal of Neurochemistry
JA  - J. Neurochem.
VL  - 125
IS  - s1
SN  - 0022-3042
UR  - https://doi.org/10.1111/jnc.12233
DO  - doi:10.1111/jnc.12233
SP  - 295
EP  - 307
PY  - 2013
ER  - 

TY  - JOUR
TI  - ADF Abstracts 2012
JO  - Experimental Dermatology
VL  - 21
IS  - 3
SN  - 0906-6705
UR  - https://doi.org/10.1111/j.1600-0625.2011.01428.x
DO  - doi:10.1111/j.1600-0625.2011.01428.x
SP  - e1
EP  - e58
PY  - 2012
ER  - 

TY  - JOUR
TI  - Selected Abstracts from Pharmacology 2018
JO  - British Journal of Pharmacology
JA  - Br J Pharmacol
VL  - 176
IS  - 16
SN  - 0007-1188
UR  - https://doi.org/10.1111/bph.14681
DO  - doi:10.1111/bph.14681
SP  - 2977
EP  - 3081
PY  - 2019
ER  - 

TY  - JOUR
TI  - Program
JO  - American Journal of Transplantation
JA  - Am J Transplant
VL  - 17
IS  - S3
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.14304
DO  - doi:10.1111/ajt.14304
SP  - 5
EP  - 204
PY  - 2017
ER  - 

TY  - JOUR
TI  - TSANZ Oral Abstracts
JO  - Respirology
VL  - 17
IS  - s1
SN  - 1323-7799
UR  - https://doi.org/10.1111/j.1440-1843.2012.02142.x
DO  - doi:10.1111/j.1440-1843.2012.02142.x
SP  - 12
EP  - 41
PY  - 2012
ER  - 

TY  - JOUR
TI  - Poster Session 3: Pediatric Liver Transplantation
JO  - Hepatology
JA  - Hepatology
VL  - 60
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.27527
DO  - doi:10.1002/hep.27527
SP  - 1595
EP  - 1604
PY  - 2014
ER  - 

TY  - JOUR
AU  - Khazim, Khaled
AU  - Azulay, Etti Ester
AU  - Kristal, Batya
AU  - Cohen, Idan
TI  - Interleukin 1 gene polymorphism and susceptibility to disease
JO  - Immunological Reviews
JA  - Immunol Rev
VL  - 281
IS  - 1
SN  - 0105-2896
UR  - https://doi.org/10.1111/imr.12620
DO  - doi:10.1111/imr.12620
SP  - 40
EP  - 56
KW  - cytokines
KW  - inflammation
KW  - interleukin 1
KW  - polymorphism
PY  - 2018
AB  - Summary The Interleukin 1 (IL-1) family plays a central role in the generation and regulation of inflammatory responses, in both innate and adaptive immunity. Although the IL-1 molecules are traditionally considered to be classical proinflammatory cytokines, their functions are not restricted to inflammation, and they have also been shown to play a key role in a wide range of additional physiological and pathological functions, including learning modulation, sleep, pregnancy, depression, appetite, hematopoiesis, metabolism, and many others. Since their effect as cytokines and regulators of inflammation is so pleiotropic, any shift of the biological balance between agonistic and antagonistic signals has the potential to cause disease. Here, we consider the genetic influence of interleukin-1 gene polymorphism in the context of susceptibility to human diseases. We review known single nucleotide polymorphisms (SNP) of IL-1 genes linked to human diseases, and suggest how exploring biological effects of IL-1 gene cluster polymorphism may lead to new directions in understanding and diagnostic of disease and effective treatment.
ER  - 

TY  - JOUR
TI  - ASBMR 27th Annual Meeting SA001–SA527
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 20
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.5650201304
DO  - doi:10.1002/jbmr.5650201304
SP  - S106
EP  - S189
PY  - 2005
ER  - 

TY  - JOUR
TI  - Program
JO  - American Journal of Transplantation
JA  - Am J Transplant
VL  - 19
IS  - S3
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.15404
DO  - doi:10.1111/ajt.15404
SP  - 5
EP  - 309
PY  - 2019
ER  - 

TY  - JOUR
TI  - Poster Session TPS 1-18
JO  - Allergy
JA  - Allergy
VL  - 71
IS  - S102
SN  - 0105-4538
UR  - https://doi.org/10.1111/all.12974
DO  - doi:10.1111/all.12974
SP  - 300
EP  - 389
PY  - 2016
ER  - 

TY  - JOUR
AU  - Pitkänen, Asla
AU  - Henshall, David C.
AU  - Cross, J. Helen
AU  - Guerrini, Renzo
AU  - Jozwiak, Sergiusz
AU  - Kokaia, Merab
AU  - Simonato, Michele
AU  - Sisodiya, Sanjay
AU  - Mifsud, Janet
TI  - Advancing research toward faster diagnosis, better treatment, and end of stigma in epilepsy
JO  - Epilepsia
JA  - Epilepsia
VL  - 60
IS  - 7
SN  - 0013-9580
UR  - https://doi.org/10.1111/epi.16091
DO  - doi:10.1111/epi.16091
SP  - 1281
EP  - 1292
KW  - biobanks
KW  - biomarker
KW  - comorbidities
KW  - databases
KW  - delivery systems
KW  - disease-modification
KW  - e-health
KW  - epileptogenesis
KW  - genetics
KW  - personalized medicine
KW  - research strategy
KW  - stigma
KW  - therapy
PY  - 2019
AB  - Abstract Seven large European Union (EU)?funded epilepsy-related research projects joined forces in May 2018 in Brussels, Belgium, in a unique community building event?the epiXchange conference. During this conference, 170 investigators from the projects DESIRE, EpimiRNA, EPISTOP, EpiTarget, EpiXchange, and EpiPGX as well as the European Reference Network EpiCARE, met up with key stakeholders including representatives of the European Commission, patient organizations, commercial partners, and other European and International groups. The epiXchange conference focused on sharing and reviewing the advances made by each project in the previous 5 years; describing the infrastructures generated; and discussing the innovations and commercial applications across five thematic areas: biomarkers, genetics, therapeutics, comorbidities, and biobanks and resources. These projects have, in fact, generated major breakthroughs including the discovery of biofluid-based molecules for diagnosis, elucidating new genetic causes of epilepsy, creating advanced new models of epilepsy, and the pre-clinical development of novel compounds. Workshop-style discussions focused on how to overcome scientific and clinical challenges for accelerating translation of research outcomes and how to increase synergies between the projects and stakeholders at a European level. The resulting advances would lead toward a measurable impact of epilepsy research through better diagnostics, treatments, and quality-of-life for persons with epilepsy. In addition, epiXchange provided a unique forum for examining how the different projects could build momentum for future novel groundbreaking epilepsy research in Europe and beyond. This report includes the main recommendations that resulted from these discussions.
ER  - 

TY  - JOUR
TI  - XXVII International Congress of the International Academy of Pathology October 12-17, 2008, Athens, Greece POSTER PRESENTATIONS
JO  - Histopathology
VL  - 53
IS  - s1
SN  - 0309-0167
UR  - https://doi.org/10.1111/j.1365-2559.2008.03116.x
DO  - doi:10.1111/j.1365-2559.2008.03116.x
SP  - 1
EP  - 432
PY  - 2008
ER  - 

TY  - JOUR
TI  - 38th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF)
JO  - Experimental Dermatology
VL  - 20
IS  - 2
SN  - 0906-6705
UR  - https://doi.org/10.1111/j.1600-0625.2010.01228.x
DO  - doi:10.1111/j.1600-0625.2010.01228.x
SP  - 162
EP  - 216
PY  - 2011
ER  - 

TY  - JOUR
TI  - SMR Congress 2017 abstracts
JO  - Pigment Cell & Melanoma Research
JA  - Pigment Cell Melanoma Res.
VL  - 31
IS  - 1
SN  - 1755-1471
UR  - https://doi.org/10.1111/pcmr.12656
DO  - doi:10.1111/pcmr.12656
SP  - 125
EP  - 230
PY  - 2018
ER  - 

TY  - JOUR
AU  - Taub, Dennis D.
TI  - Cytokine, Growth Factor, and Chemokine Ligand Database
JO  - Current Protocols in Immunology
JA  - Current Protocols in Immunology
VL  - 61
IS  - 1
SN  - 1934-3671
UR  - https://doi.org/10.1002/0471142735.im0629s61
DO  - doi:10.1002/0471142735.im0629s61
SP  - 6.29.1
EP  - 6.29.89
KW  - chemokines
KW  - cytokines
KW  - interleukins
KW  - growth factor
PY  - 2004
AB  - Abstract Cytokines, chemokines, and growth factors are soluble proteins produced by leukocytes and other cell types, which act as chemical communicators between cells and tissues within the body. These proteins mediate a number of functions, ranging from effects on cell growth, differentiation, survival, and a number of effector activities. The main purpose of this unit is to provide an easy-to-use reference summarizing some of the current information on well-established cytokine, growth factore, and chemokine ligands. The information provided is confined largely to alternative names, protein properties, genetic chracteristics, chromosomal localization, cellular expression patters, cellular-tissue targets, stimuli regulating expression, functional properties, expression analysis, and clinical utility.
ER  - 

TY  - JOUR
TI  - Workshop Sessions
JO  - Immunology
VL  - 137
IS  - s1
SN  - 0019-2805
UR  - https://doi.org/10.1111/imm.12001
DO  - doi:10.1111/imm.12001
SP  - 1
EP  - 184
PY  - 2012
ER  - 

TY  - JOUR
TI  - Poster Session
JO  - Acta Physiologica
JA  - Acta Physiol
VL  - 211
IS  - s697
SN  - 1748-1708
UR  - https://doi.org/10.1111/apha.12362
DO  - doi:10.1111/apha.12362
SP  - 62
EP  - 184
PY  - 2014
ER  - 
